Chimeric fibroblast growth factor 23 proteins and methods of use

Patent metadata

Field	Value
Publication number	US-10364278-B2
Application number	US-201715598420-A
Country	US
Kind code	B2
Filing date	May 18, 2017
Priority date	Jun 7, 2012
Publication date	Jul 30, 2019
Grant date	Jul 30, 2019

Abstract

The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the αKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

First claim

What is claimed:

1. A chimeric protein comprising:
an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an FGF1 portion beginning at any one of residues 1 to 25 and ending at any one of residues 150 to 155 of SEQ ID NO: 1,
wherein the FGF1 amino acid positions corresponding to those selected from the group consisting of N33, K127, K128, N129, K133, R134, R137, Q142, K143, and combinations thereof are substituted to decrease binding affinity for heparin and/or heparan sulfate compared to FGF1 without substitution, and
wherein the C-terminus comprises a C-terminal portion of an FGF23 comprising amino acid residues 161-251 of SEQ ID NO: 233.

2. The chimeric protein according to claim 1 , wherein the FGF1 portion is amino acid residues 1-150 of SEQ ID NO: 1.

3. The chimeric protein according to claim 1 , wherein the FGF1 portion is amino acid residues 1-151, 1-152, 1-153, 1-154, 1-155, 2-150, 2-151, 2-152, 2-153, 2-154, 2-155, 3-150, 3-151, 3-152, 3-153, 3-154, 3-155, 4-150, 4-151, 4-152, 4-153, 4-154, 4-155, 5-150, 5-151, 5-152, 5-153, 5-154, 5-155, 6-150, 6-151, 6-152, 6-153, 6-154, 6-155, 7-150, 7-151, 7-152, 7-153, 7-154, 7-155, 8-150, 8-151, 8-152, 8-153, 8-154, 8-155, 9-150, 9-151, 9-152, 9-153, 9-154, 9-155, 10-150, 10-151, 10-152, 10-153, 10-154, 10-155, 11-150, 11-151, 11-152, 11-153, 11-154, 11-155, 12-150, 12-151, 12-152, 12-153, 12-154, 12-155, 13-150, 13-151, 13-152, 13-153, 13-154, 13-155, 14-150, 14-151, 14-152, 14-153, 14-154, 14-155, 15-150, 15-151, 15-152, 15-153, 15-154, 15-155, 16-150, 16-151, 16-152, 16-153, 16-154, 16-155, 17-150, 17-151, 17-152, 17-153, 17-154, 17-155, 18-150, 18-151, 18-152, 18-153, 18-154, 18-155, 19-150, 19-151, 19-152, 19-153, 19-154, 19-155, 20-150, 20-151, 20-152, 20-153, 20-154, 20-155, 21-150, 21-151, 21-152, 21-153, 21-154, 21-155, 22-150, 22-151, 22-152, 22-153, 22-154, 22-155, 23-150, 23-151, 23-152, 23-153, 23-154, 23-155, 24-150, 24-151, 24-152, 24-153, 24-154, 24-155, 25-151, 25-152, 25-153, 25-154, or 25-155 of SEQ ID NO: 1.

4. The chimeric protein according to claim 1 , wherein the one or more substitutions are selected from the group consisting of N33T; K127D; K128Q; N129T; K133V; R134L; R137H; Q142M; K143T, K143L, or K143I; and combinations thereof.

5. A pharmaceutical composition comprising the chimeric protein according to claim 1 and a pharmaceutically-acceptable carrier.

6. The pharmaceutical composition according to claim 5 further comprising:
a hypophosphatemic agent, a phosphate binder, a vitamin D antagonist, an analgesic and/or an anti-inflammatory agent.

7. The chimeric protein according to claim 1 , wherein the FGF1 portion is amino acid residues 25-150 of SEQ ID NO: 1.

8. The chimeric protein according to claim 1 , wherein the chimeric protein comprises the amino acid sequence of SEQ ID NO: 321 or SEQ ID NO: 322.

9. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue N33.

10. The chimeric protein according to claim 9 , wherein the substitution is N33T.

11. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue K127.

12. The chimeric protein according to claim 11 , wherein the substitution is K127D.

13. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue K128.

14. The chimeric protein according to claim 13 , wherein the substitution is K128Q.

15. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue N129.

16. The chimeric protein according to claim 15 , wherein the substitution is N129T.

17. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue K133.

18. The chimeric protein according to claim 17 , wherein the substitution is K133V.

19. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue R134.

20. The chimeric protein according to claim 19 , wherein the substitution is R134L.

21. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue R137.

22. The chimeric protein according to claim 21 , wherein the substitution is R137H.

23. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue Q142.

24. The chimeric protein according to claim 23 , wherein the substitution is Q142M.

25. The chimeric protein according to claim 1 , wherein the one or more amino acid substitutions comprises a substitution at amino acid residue K143.

26. The chimeric protein according to claim 25 , wherein the substitution is K143T.

27. The chimeric protein according to claim 25 , wherein the substitution is K143L.

28. The chimeric protein according to claim 25 , wherein the substitution is K143I.

29. The chimeric protein of claim 1 , wherein the one or more amino acid substitutions comprises substitutions at amino acid residues K127, K128, and K133.

30. The chimeric protein of claim 29 , wherein the one or more amino acid substitutions are K127D, K128Q, and K133V.

Assignees

• Univ New York

Inventors

• Mohammadi Moosa
• Goetz Regina

Classifications

• A61K38/1825

  Fibroblast growth factor [FGF] · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K14/501

  acidic FGF [aFGF] · CPC title

• C07K14/50 Primary

  Fibroblast growth factor [FGF] · CPC title